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Abstract
A recent meta-analysis puts another nail in the coffin of a therapy
that held great promise for management of acute respiratory
distress syndrome. Two papers further highlight the growing
controversy surrounding the safety profile of drotrecogin alfa
(activated) and increase the clamour for a new independent trial.
Also covered are steroids and their role in preventing postoperative
atrial fibrillation, and success in instituting hypothermia after
cardiac arrest. Finally, which form of renal replacement therapy
should we be using in the intensive care unit?
Nitric oxide: a promising therapy laid to rest?
In 1976, Ashbaugh first described acute lung injury/acute
respiratory distress syndrome. Our subsequent understan-
ding of the underlying pathophysiology has grown enor-
mously and led to the development of many novel therapies.
However, the high mortality rate has changed little in
40 years. Inhaled nitric oxide (NO) was one such therapy. It
seemed perfect, being a selective pulmonary vasodilator
resulting in reversal of pulmonary shunt, reduction in
pulmonary artery pressure and improved right ventricular
function, not to mention its inhibition of platelet aggregation
and neutrophil adhesion. The clever money was on NO.
Sadly, all that sparkles is not gold. A multitude of studies have
simply failed to demonstrate improved outcomes. Despite
this, its clinical application has continued, albeit somewhat
piecemeal.
In April the British Medical Journal published a systematic
review and meta-analysis on the effect of NO in acute lung
injury [1]. Outcomes included oxygenation, pulmonary artery
pressure, duration of ventilation, mortality and adverse
effects. Twelve randomized controlled trials (n = 1,237) were
selected. The results and conclusions do not make for happy
reading. NO was found not to improve mortality, duration of
ventilation, or number of ventilator-free days. It bestowed a
small oxygenation benefit in the first few days of use. It did
not significantly reduce mean pulmonary arterial pressure.
High-dose NO (80 ppm) was associated with methaemo-
globinaemia and raised blood nitrogen dioxide levels. Finally,
a statistically significant risk for renal dysfunction was
identified in patients receiving NO, although the authors
stressed cautious interpretation of this finding.
This was an assiduously conducted review and the results
are in keeping with previous work [2]. It leaves one
begrudgingly accepting the authors’ conclusions that, ‘given
the best available evidence suggests no survival advantage
and possible increased mortality and renal dysfunction with
nitric oxide, we do not recommend its routine use’.
Drotrecogin alfa (activated): translating
research into clinical practice
Hardly a day seems to pass without further drotrecogin alfa
(activated; DAA) scandal and controversy. Concerns centre
on the widespread implementation of this drug in the
treatment of severe sepsis, based upon a single industry-
sponsored trial and the applicability of this trial to ‘real’
patient populations. Many questions persist surrounding the
indications for use and risk/benefit profile in patient sub-
groups. Bleeding risk is of particular concern.
Two recent publications are pertinent to this topic [3,4].
Bertolini and coworkers [3] reported a prospective
pharmaco-surveillance programme monitoring the use of DAA
in Italian ICUs between 2003 and 2006. The authors
attempted to compare those who received DAA with a
parallel nonrandomized untreated (control) group. The control
group consisted of patients from a different study who were
eligible for treatment with DAA but did not receive it. The
authors reported a number of key observations. First, they
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identified a high incidence of off-license prescribing. This was
largely attributable to administration commencing more than
48 hours after the onset of organ dysfunction. More worryingly,
they report a higher incidence of both serious bleeding and
other fatal and life-threatening events compared with the
previous landmark studies [5,6]. The also observed that
intensive care unit (ICU) mortality rates for treatment and
control groups (46.5% and 54.9%, respectively) were much
higher than the 28-day mortality in the aforementioned trials.
This begs the question as to how well the PROWESS
(Recombinant Human Activated Protein C Worldwide Evalua-
tion of Severe Sepsis) population was representative of the
real target population. The second report is of a retrospective
observational study of the use of DAA in Canada. Findings
are strikingly similar to those of the study reported by Bertolini
and coworkers. Both mortality rate and the incidence of
serious bleeding were significantly greater than in
PROWESS. However, early treatment with DAA (within
12 hours) was an independent predictor of survival.
Neither of these studies allows firm conclusions to be drawn
as to the optimal indication for DAA and the precise risk/
benefit profiles for various patient subgroups (for instance,
surgical versus nonsurgical, or high versus low risk for death).
However, they both cast further doubt as to the general
applicability of PROWESS to the every day clinical setting
and population. An accompanying editorial [7] emphasizes
the urgent need for high quality, independent confirmatory
research to identify those patients who are most likely to
benefit from this therapy.
Matters cardiac
Atrial fibrillation (AF) is both common and troublesome. New-
onset AF in the critically ill patient is related to the systemic
inflammatory response, and is often refractory to treatments
such as digoxin and amiodarone. A recent report published in
the Journal of the American Medical Association [8] suggests
that steroids are efficacious in prophylaxis against acute AF. A
Finish group conducted a double blind randomized controlled
trial, in which patients with no prior history of AF undergoing
cardiac surgery were randomly assigned to preoperative and
postoperative (3 days) hydrocortisone or placebo. The
incidence of postoperative AF was significantly lower in the
steroid group (30% versus 48%). No adverse effects were
noted. The authors postulate an anti-inflammatory mechanism,
although they also suggest that the antiemetic effect of
steroids is also of benefit in terms of absorption of oral
medications such as metoprolol, which all patients received.
Clearly, this group of patients exhibits a high incidence of AF,
higher than that in the general ICU population, and steroids
have only been shown to be efficacious in preventing AF
rather than treating established AF. As such, extrapolating this
study to all ICU patients is probably flawed.
As alluded to above, translation of a therapeutic intervention
from a clinical trial to reality is often fraught. This may be
because of the study population not being representative of
the target population, unrealistic/irreproducible protocols, or
failure to capture the collective consciousness. In 2002, two
papers were published in the New England Journal of
Medicine that detailed evidence for improved outcomes
following cardiac arrest with induced mild hypothermia
[9,10]. August bodies such as the International Liaison
Committee on Resuscitation have since recommended this
therapeutic intervention, but is it happening on the shop
floor? Arrich [11] decided to find out. In this observational
study, data were collected from 19 European sites between
2003 and 2005. All patients presenting with return of
spontaneous circulation (ROSC) after cardiac arrest were
considered. Exclusions were similar to those in previous
studies. The primary end-point was the cooling protocol,
including the interval from arrest and ROSC to initiation of
cooling, the cooling rate, cooling duration and re-warming
rate. Secondary end-points were complications and neuro-
logical outcome. Results were very encouraging, with 79% of
patients undergoing hypothermia. The median time from
ROSC to cooling was 159 min, which was longer than that
achieved in a recent clinical trial. However, the cooling rate of
1.1°C/hour was far superior to that in clinical trials. Cooling
was maintained for an average of 24.3 hours. Rates of
adverse events were lower than previously reported.
Neurological outcome was better in the hypothermia group.
This study demonstrates that therapeutic hypothermia is both
feasible and safe in normal clinical practice, and that it
benefits patients. No excuses then!
Intermittent haemodialysis versus continuous
renal replacement therapy
Debate surrounding the pros and cons of intermittent haemo-
dialysis (IHD) versus continuous renal replacement therapy
(CRRT) in the ICU for the management of acute renal failure
grumbles on. In the UK CRRT predominates, and
serendipitously this appears to be the better choice. A
Swedish group recently reported a large nationwide
retrospective cohort study of renal outcome from acute renal
failure following either IHD or CRRT (n = 2,202) [12]. Both
groups were well matched before ICU admission, with an
overall mortality of 50%. There was no difference in 90-day
mortality between groups, which is in keeping with previous
studies. However, patients treated with IHD were at
significantly greater risk for chronic renal failure (need for renal
replacement therapy at 3 months) and for being dialysis
dependent, and unsurprisingly this group had the greatest
long-term mortality. This was so despite data suggesting that
patients in the CRRT group were sicker than those in the IHD
group. Although clearly not a perfect study, this adds to the
growing body of evidence indicating that CRRT is the renal
replacement therapy of choice in the ICU. The authors suggest
that a global re-evaluation of RRT in the ICU should now occur.
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